Table 5.

Treatment results according to presented features in all children treated in AML-BFM 2004 Interim study

Factors	No. of total patients	Overall survival ± SE (%)		Event-free survival ± SE (%)		No. of patients with achieved CR (%)	Relapse-free survival ± SE (%)
		5 year	p-value	5 year	p-value		5 year	p-value
Gender
Male	130	63.9 ± 4.5	0.59	54.6 ± 4.6	0.24	119	62.5 ± 4.8	0.51
Female	107	62.1 ± 4.9		48.5 ± 5.1		88	65.3 ± 5.8
Age at diagnosis (year)
< 2	40	57.4 ± 7.8	0.47	45.7 ± 8.2	0.46	36	58.2 ± 9.2	0.36
2–10	62	68.5 ± 6.2		50.4 ± 6.6		53	63.7 ± 7.1
> 10	135	62.5 ± 4.5		54.3 ± 4.6		118	65.3 ± 4.9
WBC ´ 109
< 20	121	68.6 ± 4.5	0.31	62.3 ± 4.6	0.026	110	75.9 ± 4.6	0.003
20–100	75	56.8 ± 6.1		40.8 ± 6.2		63	50.2 ± 7.0
> 100	41	58.4 ± 8.0		40.9 ± 8.1		34	50.6 ± 9.4
FAB type
M0	21	66.9 ± 11.4	0.07	63.5 ± 11.3	0.16	18	67.9 ± 12.1	0.09
M1	32	63.3 ± 9.6		55.4 ± 9.5		28	65.2 ± 10.2
M2	66	68.7 ± 6.1		52.2 ± 6.3		62	61.3 ± 6.7
M3	20	74.6 ± 9.8		64.0 ± 12.9		16	82.9 ± 11.3
M4	48	66.2 ± 6.9		52.6 ± 7.4		43	65.6 ± 7.8
M5	36	43.9 ± 8.7		31.3 ± 8.4		29	42.9 ± 10.6
M6 + M7	14	53.8 ± 13.8		53.8 ± 13.8		11	88.9 ± 10.4

The values in italics denotes close statistical significance